AU2015376851B2 - Glypican epitopes and uses thereof - Google Patents

Glypican epitopes and uses thereof Download PDF

Info

Publication number
AU2015376851B2
AU2015376851B2 AU2015376851A AU2015376851A AU2015376851B2 AU 2015376851 B2 AU2015376851 B2 AU 2015376851B2 AU 2015376851 A AU2015376851 A AU 2015376851A AU 2015376851 A AU2015376851 A AU 2015376851A AU 2015376851 B2 AU2015376851 B2 AU 2015376851B2
Authority
AU
Australia
Prior art keywords
seq
epitope
variant
segment
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015376851A
Other languages
English (en)
Other versions
AU2015376851A1 (en
Inventor
Douglas Campbell
Irene JUSTINIANO FUENMAYOR
Aline NOCON
Julie SOON
Quach TRUONG
Bradley Walsh
Sandra Wissmueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minomic International Ltd
Original Assignee
Minomic International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minomic International Ltd filed Critical Minomic International Ltd
Publication of AU2015376851A1 publication Critical patent/AU2015376851A1/en
Application granted granted Critical
Publication of AU2015376851B2 publication Critical patent/AU2015376851B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015376851A 2015-01-16 2015-01-16 Glypican epitopes and uses thereof Active AU2015376851B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU2015/000019 WO2016112423A1 (en) 2015-01-16 2015-01-16 Glypican epitopes and uses thereof

Publications (2)

Publication Number Publication Date
AU2015376851A1 AU2015376851A1 (en) 2017-07-27
AU2015376851B2 true AU2015376851B2 (en) 2020-07-09

Family

ID=56405046

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015376851A Active AU2015376851B2 (en) 2015-01-16 2015-01-16 Glypican epitopes and uses thereof

Country Status (11)

Country Link
US (3) US20180002391A1 (enExample)
EP (1) EP3245219B1 (enExample)
JP (1) JP6735005B2 (enExample)
KR (1) KR102435383B1 (enExample)
CN (1) CN107531755B (enExample)
AU (1) AU2015376851B2 (enExample)
CA (1) CA2973771A1 (enExample)
DK (1) DK3245219T3 (enExample)
ES (1) ES2805085T3 (enExample)
SG (1) SG11201705808XA (enExample)
WO (1) WO2016112423A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108734B (zh) 2014-10-23 2021-09-14 美侬米克国际有限公司 单克隆抗gpc-1抗体和其用途
AU2016250900B2 (en) * 2015-04-20 2022-03-17 GlyTherix Ltd. Therapeutic antibodies and uses thereof
US20200308299A1 (en) * 2017-04-28 2020-10-01 National University Corporation Kochi University Anti-gpc-1 antibody
AU2020212534A1 (en) * 2019-01-22 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN111187350A (zh) * 2019-12-30 2020-05-22 西安英创生物技术有限公司 一种与磷脂酰肌醇蛋白聚糖-1结合的抗原结合蛋白
IT202200021546A1 (it) 2022-10-19 2024-04-19 Centro Di Riferimento Oncologico Di Aviano Anticorpo monoclonale anti-GPC1, suoi usi terapeutici e diagnostici
WO2025202359A1 (en) * 2024-03-27 2025-10-02 Adcendo Aps Anti-gpc1 antibodies and uses thereof
WO2025202361A1 (en) * 2024-03-27 2025-10-02 Adcendo Aps Anti-gpc1 antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1999037764A2 (en) * 1998-01-27 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie New members of the glypican gene family
CA2346264A1 (en) * 1998-10-16 2000-04-27 Regents Of The University Of California Glypicans for the detection and treatment of human carcinoma
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
EP2208784B1 (en) * 2001-06-22 2013-01-02 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican 3 antibody
DE602005024502D1 (de) * 2004-07-09 2010-12-16 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8270389B2 (en) 2008-08-11 2012-09-18 Marvell International Ltd. Method of synchronization for low power idle
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUHOVSKIH, A. et al., "Proteoglycan Expression in Normal Human Prostate Tissue and Prostate Cancer.", ISRN Oncology, (2013), vol. 2013, page 680136 *

Also Published As

Publication number Publication date
US20240247037A1 (en) 2024-07-25
EP3245219B1 (en) 2020-04-08
EP3245219A1 (en) 2017-11-22
EP3245219A4 (en) 2018-06-06
CA2973771A1 (en) 2016-07-21
KR20170109584A (ko) 2017-09-29
DK3245219T3 (da) 2020-06-29
AU2015376851A1 (en) 2017-07-27
SG11201705808XA (en) 2017-08-30
US20210107958A1 (en) 2021-04-15
JP6735005B2 (ja) 2020-08-05
JP2018504903A (ja) 2018-02-22
ES2805085T3 (es) 2021-02-10
CN107531755B (zh) 2022-02-25
CN107531755A (zh) 2018-01-02
WO2016112423A1 (en) 2016-07-21
US20180002391A1 (en) 2018-01-04
KR102435383B1 (ko) 2022-08-24

Similar Documents

Publication Publication Date Title
AU2015376851B2 (en) Glypican epitopes and uses thereof
JPWO2004081047A1 (ja) モノクローナル抗体及びこれを産生するハイブリドーマ
CN107001453B (zh) 结合人p53线性表位的抗体及其诊断应用
JP2011160681A (ja) Ａ型インフルエンザのヘマグルチニンに対する抗体およびその利用
CN118255884A (zh) 一组Nova-1蛋白的单克隆抗体及其产品和检测Nova-1蛋白的方法
US20240210403A1 (en) Lateral flow analysis and breast cancer
CN109627306A (zh) 水稻籽粒谷蛋白GluA2亚基的抗原表位、其抗体及应用
EP2700650B1 (en) Monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof
CN102863530A (zh) 一种脂肪细胞分化代谢产物igf-1抗体及包含该抗体的芯片以及应用
KR101329344B1 (ko) 돼지인플루엔자 바이러스 헤마글루티닌 검출용 항체 및 이의 용도
KR101994977B1 (ko) c-Myc에 특이적인 단클론 항체 및 그 용도
JP7053058B2 (ja) グリピカンエピトープおよびその使用
WO2023154780A1 (en) Anti-her2/neu antibodies and methods of use
WO2010006601A1 (en) Pax 5 monoclonal antibody
JP6861349B2 (ja) Ｃｄ８１ ｌｅｌ特異的モノクローナル抗体
JP6099393B2 (ja) オートタキシンアイソフォーム特異的抗体および検出方法
HK1238267B (en) Glypican epitopes and uses thereof
CN108727493B (zh) 抗Stathmin单克隆抗体及其用途
KR101329342B1 (ko) 돼지인플루엔자 바이러스 뉴라미니다아제 검출용 항체 및 이의 용도
KR102218561B1 (ko) 단일클론항체 쌍을 이용한 뎅기 바이러스의 검출 방법
HK1241896A1 (en) Antibody binding a linear epitope of human p53 and diagnostic applications thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)